 |
年间契约型资讯服务
商品编码
1876165
创造新机会：肿瘤XDC市场Unlocking Opportunity: Dominate the Market of Conjugated Drugs (XDCs) in Oncology with Confidence |
||||||
XDC正在革新癌症治疗，开启精准治疗、条件性活化和治疗潜力的新篇章。然而，在快速发展、激烈竞争和不断扩充的研发管线中，保持领先地位需要的不仅是洞察力，更需要前沿知识、策略远见和数据驱动的决策。
光在2024/25年度，肿瘤研发管线就迎来了一波创新浪潮，预计将有436种新型XDC、超过972个药物事件，以及涵盖2505个药物项目的共计10642个事件。这清晰地证明了该领域发展速度的加快和复杂性的增加。
隆重推出肿瘤XDC分析工具，这是一款全面的解决方案，可协助您驾驭这一充满活力的领域，追踪新兴趋势，并掌握突破性机会。
探索该领域奥秘的终极工具：
- XDC（药物偶联物）是一类多样化且快速发展的癌症治疗药物，至少包含七种不同的形式：抗体药物偶联物 (ADC)、胜肽药物偶联物 (PDC)、小分子药物偶联物 (SMDC)、放射免疫偶联物 (RDC)、寡核苷酸药物偶联物 (ODC)、奈米药物偶联物和酵素药物偶联物。这是一个充满活力的研究领域，正在重塑精准癌症治疗的模式。
- XDC 的有效载荷代表了肿瘤学中最有效且种类最丰富的药物类别，包括微管抑制剂、DNA 损伤剂、拓朴异构酶抑制剂、放射性同位素、免疫调节剂和基因调节剂。 每种有效载荷都经过精心挑选和设计，旨在最大限度地杀伤肿瘤细胞，同时最大限度地减少全身暴露，因此有效载荷的创新是XDC领域治疗效果和差异化的关键推动因素。
- 连接子技术是XDC性能的分子基石，它透过可裂解（pH敏感、酶敏感）和不可裂解连接子等创新技术，精确控制有效载荷的释放。连接子的选择直接影响稳定性、药物动力学和肿瘤选择性，为优化XDC平台的安全性、有效性和治疗指数提供了策略性槓桿。
- 条件活化策略为XDC赋予了强大的精准性，透过低pH值、肿瘤相关酶、缺氧和氧化还原梯度等触发因素，使有效载荷仅在肿瘤微环境中释放。这种肿瘤选择性活化最大限度地减少了脱靶效应，提高了治疗指数，代表了更聪明、更安全的下一代药物递送方法。
- 双特异性和多特异性抗体偶联药物（ADC）的出现标誌着标靶治疗的新纪元，能够同时活化多种肿瘤抗原和免疫效应路径。这种方法增强了肿瘤选择性，克服了抗原异质性，并为双重有效载荷递送和免疫系统调节开闢了新的机遇，使其处于XDC领域创新前沿。
其影响为何？快速扩展的临床研发管线、突破性的FDA批准以及激增的投资机会，使XDC领域成为当今肿瘤学领域最令人振奋的前沿领域之一。
六大突破性优势：
"肿瘤学XDC分析工具" 的功能
- 竞争对手追踪 - 监控活跃的机构、新药、目标分子和技术
- 加速许可和合作 - 联繫领先的生物技术开发商、业务拓展和许可专业人士以及学术项目
- 助力高影响力报告和演示 - 利用近乎即时的市场情报推动数据驱动的决策 - 所有数据均可汇出为预置的图表
- 与关键意见领袖 (KOL) 互动 - 与领先的临床和科学专家建立联繫
- 寻找合适的投资者 - 利用专注于肿瘤学的融资伙伴网络
- 掌握产业动态 - 分析全球主要肿瘤学会议（AACR、ASCO、ESMO、ASH 等）的数据
肿瘤学XDC分析工具持续透过持续更新和每月电子邮件提醒，让您随时掌握最新动态。
数千种药物、标靶、公司、临床试验、交易等等，尽在您的指尖。
触手可及的支持与灵感：
将我们的专业知识转化为您的虚拟业务拓展团队。我们提供全天候 (24/7) 支持，随时为您提供协助。我们丰富的操作指南影片库提供经过验证的最佳实务。从竞争对手产品线分析到使用者贡献的案例研究，您将找到可操作的见解来改善您的工作。
与您共同成长的工具：
与提供时间快照的静态报告不同，我们的分析工具提供一年的线上存取权限。这包括近乎即时的更新、新功能、产品线提醒和专属支援。
如果您想更进一步，可以无缝续订或升级到业界领先的全方位服务平台 1stOncology。 1stOncology 是您在癌症药物研发领域的全面合作伙伴。
系统需求：
- 基于 Web 的应用程序，与主流浏览器（Chrome、Firefox、Safari、Internet Explorer）
- 需要网路连接
取得无与伦比的智慧讯息，助力肿瘤药物研发的策略决策
该工具由屡获殊荣的人工智慧 (AI) 增强型智慧平台提供支援，该平台拥有超过 25 年的肿瘤学专业知识，可在肿瘤药物研发的各个阶段提供无与伦比的全面业务、竞争和临床智慧资讯。
在业务拓展和探索/评估方面，它提供了对全球肿瘤领域无与伦比的洞察力，涵盖从技术、靶点和新创公司到製药公司、学术和商业机会，并作为一个强大的交易资料库，整合了许可协议资讯和数千笔历史交易。
在临床开发方面，我们拥有业界领先的超过3000种生物标记情报库，追踪它们作为分层、预测和药效学标记物的作用，同时涵盖从早期到获批的伴随诊断工作。我们独特的早期成功/失败指标清楚地突出了临床开发领域的领导者和落后者，帮助您监测和预测不断变化的市场格局。
我们的临床试验情报不仅限于终点，还涵盖给药细节、抗药性机制、不良事件、食物影响、试验阶段和进展、首次人体试验 (FIH)、肿瘤分期/分级和治疗线 (LoT)，从而提供试验格局的全面视图。
我们简化了联合疗法开发的复杂性，将标靶、药物模式、适应症和试验阶段分解，建构出不断演进的策略图谱，从而实现快速的策略决策。
最后，我们将真实世界数据 (RWE) 与针对每个开发阶段量身定制的多方面分析相结合。我们的工具涵盖所有区隔领域——药物模式、联合用药概况、生物标记集群——能够提供深入的背景洞察，并推动肿瘤研发领域更快、更聪明、更实证的决策。
肿瘤分析工具中偶联药物 (XDC) 覆盖范围区隔
| 竞争对手概览 | |
|---|---|
监测机构数量： |
超过 1,200 家 |
| 公司 | 1,061 |
| 非营利组织 | 606 |
| 公共组织 | 352 |
| 学术机构 | 114 |
| 新创企业 | 115 |
| 癌症中心/医院 | 40 |
| 大型製药/生技公司 | 36 |
五大药物研发公司： |
|
排名前五的国家： |
|
| 研发管线 | |
|---|---|
|
药物总数： |
|
| 交易与合作 | |
|---|---|
|
过去 5 年的交易数量： |
|
| 融资与投资人 | |
|---|---|
|
融资状况（过去 5 年）： |
|
The world of conjugated drugs (XDCs) is transforming cancer treatment, unlocking new levels of precision, conditional activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.
In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 436 new conjugated drugs, over 972 drugs with events, and 10,642 total events spanning 2,505 total drug programs - a clear signal of the accelerating pace and complexity in this space.
Introducing the Conjugated Drugs (XDCs) in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.
The Ultimate Tool for Exploring What Makes This Field So Exciting:
- XDCs represent a versatile and rapidly evolving class of cancer therapeutics, with at least seven distinct formats - Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates (PDCs), Small Molecule-Drug Conjugates (SMDCs), Radioimmunoconjugates (RDCs), Oligonucleotide-Drug Conjugates (ODCs), Nanoparticle-Drug Conjugates, and Enzyme-Drug Conjugates - making this a highly dynamic space to watch as it reshapes the landscape of precision oncology.
- XDC payloads are among the most potent and diverse agents in oncology, including microtubule inhibitors, DNA-damaging agents, topoisomerase inhibitors, radioactive isotopes, immune- and gene modulators - each carefully selected and engineered to maximize tumor killing while minimizing systemic exposure, making payload innovation a critical driver of therapeutic impact and differentiation in the XDC space.
- Linker technology is the molecular lynchpin of XDC performance, enabling precise control over payload release through innovations like cleavable (pH-sensitive, enzyme-sensitive) and non-cleavable linkers. The choice of linker directly impacts stability, pharmacokinetics, and tumor selectivity, making it a strategic lever in optimizing safety, efficacy, and therapeutic index across XDC platforms.
- Conditional activation strategies add a powerful layer of precision to XDCs, enabling payload release specifically in the tumor microenvironment through triggers such as low pH, tumor-associated enzymes, hypoxia, or redox gradients. This tumor-selective activation enhances therapeutic index by minimizing off-target effects and represents a next-generation approach to smarter, safer drug delivery.
- The emergence of bi- and multispecific ADCs marks a new era in targeted therapy, enabling simultaneous engagement of multiple tumor antigens or immune effector pathways. This approach enhances tumor selectivity, overcomes antigen heterogeneity, and opens new opportunities for dual payload delivery or immune system modulation, making it a frontier of innovation in the XDC landscape.
The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the XDC field one of the most exciting frontiers in oncology today.
6 Game-Changing Benefits for You:
With the Conjugated Drugs in Oncology Analytical Tool you will:
- Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
- Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
- Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
- Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
- Find the Right Investors - tap into a network of oncology-focused funding partners
- Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)
Your Conjugated Drugs (XDCs) in Oncology Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.
You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of our near real-time coverage.
Support & Inspiration at Your Fingertips:
Leverage our expertise as your virtual business development team-ready when you are. Our 24/7 support ensures help is always available, while our rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work.
A Tool That Grows With You:
Unlike static reports that offer just a snapshot in time, our Analytical Tools provide a full year of online access-complete with near real time updates, new features, pipeline alerts, and dedicated support. When you're ready to go further, you can seamlessly renew your access or upgrade to our industry-leading full-service platform: 1stOncology-your comprehensive partner in oncology drug development.
System Requirements:
- Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
- Internet access
Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development
This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.
For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.
In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.
Our clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.
We simplify the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.
Finally, we integrate Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.
Coverage Breakdown from your Conjugated Drugs (XDCs) in Oncology Analytical Tool
| Competitor Overview | |
|---|---|
|
Organizations Monitored: |
|
|
Organization Types:
Corporate |
|
Top 5 Drug Developers: |
|
Top 5 Nations: |
|
| Pipeline | |
|---|---|
|
Total No Drugs: |
|
| Deals & Alliances | |
|---|---|
|
No. Deals (Last 5 Years): |
|
| Funding & Investors | |
|---|---|
|
Funding (Last 5 Years): |
|
